MARIMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 USD | -0.64% |
|
-5.66% | -9.02% |
| May. 09 | Transcript : MariMed Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 08 | MariMed Inc. Provides Earning Guidance for the Full Year 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in debt and has limited leeway for investment
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -9.02% | 95.52M | - | ||
| +18.70% | 3.08B | D+ | ||
| +18.71% | 1.77B | - | ||
| +97.67% | 678M | - | ||
| +11.82% | 527M | - | ||
| +40.38% | 174M | - | ||
| -2.51% | 98.29M | - | - | |
| +37.50% | 67.59M | - | C | |
| +40.45% | 57.04M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- MRMD Stock
- Ratings MariMed Inc.